Ranking differential drug activities from dose-response synthetic lethality screens

Journal of Biomolecular Screening

Volumn 21, Issue 9, 2016, Pages 942-955

  Guha, Rajarshi ^a   Mathews Griner, Lesley A ^a   Keller, Jonathan M ^a   Zhang, Xiaohu ^a   Fitzgerald, David ^b   Antignani, Antonella ^b   Pastan, Ira ^b   Thomas, Craig J ^a   Ferrer, Marc ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

immunotoxin; qHTS; ranking; synthetic lethal screen

Indexed keywords

ABIRATERONE; ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; AROMATASE; AROMATASE INHIBITOR; BAZEDOXIFENE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL BLOCKING AGENT; CAROVERINE; CISPLATIN; DASATINIB; DOXORUBICIN; EVEROLIMUS; GEMCITABINE; IMMUNOTOXIN; LIPOXYGENASE INHIBITOR; NIGULDIPINE; NILOTINIB; OSANETANT; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROSTANOID; PROTEASOME; SALINOMYCIN; UNINDEXED DRUG; VAPIPROST; VASCULOTROPIN RECEPTOR 1; VISMODEGIB; WITHAFERIN A; ZILEUTON; BACTERIAL TOXIN; EXOTOXIN; MOXETUMOMAB PASUDOTOX;

AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DATA ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; LETHALITY; NEOPLASM; NONPARAMETRIC TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; LETHAL MUTATION; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES; THERAPEUTIC USE;

BACTERIAL TOXINS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOTOXINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; SMALL MOLECULE LIBRARIES; SYNTHETIC LETHAL MUTATIONS;

EID: 84988486109     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057116644890     Document Type: Article

References (26)

1. Chan D. A., Giaccia A. J., Harnessing Synthetic Lethal Interactions in Anticancer Drug Discovery. Nat. Rev. Drug Discov. 2011, 10, 351-364.
2. Prahallad A., Bernards R., Opportunities and Challenges Provided by Crosstalk between Signalling Pathways in Cancer. Oncogene 2016, 35, 1073-1079.
3. Kaelin W. G. Jr., The Concept of Synthetic Lethality in the Context of Anticancer Therapy. Nat. Rev. Cancer 2005, 5, 689-698.
4. Ferrari E., Lucca C., Foiani M., A Lethal Combination for Cancer Cells: Synthetic Lethality Screenings for Drug Discovery. Eur. J. Cancer 2010, 46, 2889-2895.
5. Jang I. S., Neto E. C., Guinney J., et al. Systematic Assessment of Analytical Methods for Drug Sensitivity Prediction from Cancer Cell Line Data. Pac. Symp. Biocomput. 2014, 19, 63-74.
6. Fallahi-Sichani M., Honarnejad S., Heiser L. M., et al. Metrics Other Than Potency Reveal Systematic Variation in Responses to Cancer Drugs. Nat. Chem. Biol. 2013, 9, 708-714.
7. Inglese J., Auld D. S., Jadhav A., et al. Quantitative High-Throughput Screening: A Titration-Based Approach That Efficiently Identifies Biological Activities in Large Chemical Libraries. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 11473-11478.
8. Zhang J. H., Kang Z. B., Ardayfio O., et al. Application of Titration-Based Screening for the Rapid Pilot Testing of High-Throughput Assays. J. Biomol. Screen. 2013, 19, 651-660.
9. Wang Y., Jadhav A., Southal N., et al. A Grid Algorithm for High Throughput Fitting of Dose-Response Curve Data. Curr. Chem. Genomics 2010, 4, 57-66.
10. Haibe-Kains B., El-Hachem N., Birkbak N. J., et al. Inconsistency in Large Pharmacogenomic Studies. Nature 2013, 504, 389-393.
11. Bang S., Nagata S., Onda M., et al. HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. Clin. Cancer Res. 2005, 11, 1545-1550.
12. Pastan I., Hassan R., Fitzgerald D. J., et al. Immunotoxin Therapy of Cancer. Nat. Rev. Cancer 2006, 6, 559-565.
13. Kreitman R. J., Tallman M. S., Robak T., et al. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients with Hairy Cell Leukemia. J. Clin. Oncol. 2012, 30, 1822-1828.
14. Wayne A. S., Fitzgerald D. J., Kreitman R. J., et al. Immunotoxins for Leukemia. Blood 2014, 123, 2470-2477.
15. Mathews L. A., Keller J. M., Goodwin B. L., et al. A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells. J. Biomol. Screen. 2012, 17, 1231-1242.
16. Atkinson K., An Introduction to Numerical Analysis; John Wiley: New York, 1989; 2nd ed.
17. Southall N., A., J., Huang R., et al. Enabling the Large Scale Analysis of Quantitative High Throughput Screening Data. In Handbook of Drug Screening; Seethala R., Zhang L., Eds.; CRC Press: Boca Raton, FL, 2009; pp. 442-464.
18. Birmingham A., Selfors L. M., Forster T., et al. Statistical Methods for Analysis of High-Throughput RNA Interference Screens. Nat. Methods 2009, 6, 569-575.
19. Bansal M., Yang J., Karan C., et al. A Community Computational Challenge to Predict the Activity of Pairs of Compounds. Nat. Biotech. 2014, 32, 1213-1222.
20. Costello J. C., Heiser L. M., Georgii E., et al. A Community Effort to Assess and Improve Drug Sensitivity Prediction Algorithms. Nat. Biotech. 2014, 32, 1202-1212.
21. Breitling R., Armengaud P., Amtmann A., et al. Rank Products: A Simple, Yet Powerful, New Method to Detect Differentially Regulated Genes in Replicated Microarray Experiments. FEBS Lett. 2004, 573, 83-92.
22. Eisinga R., Breitling R., Heskes T., The Exact Probability Distribution of the Rank Product Statistics for Replicated Experiments. FEBS Lett. 2013, 587, 677-682.
23. 2 from Contingency Tables, and the Calculation of P. J. R. Stat. Soc. 1922, 85, 87-94.
24. Zhang J. H., Chung T. D., Oldenburg K. R., A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
25. Borisy A. A., Elliott P. J., Hurst N. W., et al. Systematic Discovery of Multicomponent Therapeutics. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 7977-7982.
26. Mathews Griner L. A., Guha R., Shinn P., et al. High-Throughput Combinatorial Screening Identifies Drugs That Cooperate with Ibrutinib to Kill Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 2349-2354.